Lilly's tirzepatide delivered up to 22.5% weight prepaidbill online loss in adults with obesity or overweight in SURMOUNT-1

Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study63% of participants taking tirzepatide 15 mg achieved at least 20% body weight reductions as a key secondary endpointINDIANAPOLIS, April 28, 2023 /PRNewswire/ — Tirzepatide (5 mg, 10 mg, 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in topline results from Eli Lilly and Company’s (NYSE: LLY) SURMOUNT-1 clinical trial, with participants losing up to 22.5% (52 lb. or 24 kg) of their body weight for the efficacy estimandi.

Author: Finanzen.Net Gmbh